Strongest quarter in eight years
18/10/19 -"Roche’s Q3 19 sales growth of 13% CER is the highest quarterly growth in the last eight years. In oncology, the newer drugs have clearly taken over the growth baton from the older ones, further ..."
Pages
69
Language
English
Published on
18/10/19
You may also be interested by these reports :
26/04/24
The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International ...
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...